Subgram daily supplementation with docosahexaenoic acid protects low-density lipoproteins from oxidation in healthy men. 2010

Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
Université de Lyon, F-69622, Lyon, France. Catherine.Calzada@insa-lyon.fr

OBJECTIVE To determine the effect of supplementation with increasing doses of docosahexaenoic acid (DHA), as the only n-3 polyunsaturated fatty acid (PUFA), on low-density lipoprotein (LDL) redox status and oxidizability. METHODS Twelve healthy men aged 53-65 years ingested consecutive doses of DHA (200, 400, 800 and 1600 mg/day), each dose for two weeks. RESULTS The proportions of DHA increased dose-dependently in LDL phospholipids and cholesteryl esters, even after two weeks of supplementation with 200mg/day DHA. The daily intake of 200, 400 and 800 mg DHA resulted in increased alpha-tocopherol concentrations, decreased MDA concentrations, and a longer lag time for copper-induced LDL oxidation. Supplementation with 1600 mg/day DHA had no effect on the above parameters. In plasma, concentrations of 4-hydroxy-hexenal, specifically derived from the peroxidation of n-3 fatty acids, significantly increased after 800 and 1600 mg DHA, representing 0.01% of plasma n-3 PUFAs, while 4-hydroxy-nonenal concentrations, derived from the peroxidation of n-6 fatty acids, did not change. CONCLUSIONS Our results clearly show that an intake of 200-800 mg/day DHA may have protective and antioxidant effects on LDL and could represent optimal doses for cardiovascular disease prevention in a healthy population.

UI MeSH Term Description Entries
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297 Male Males
D008315 Malondialdehyde The dialdehyde of malonic acid. Malonaldehyde,Propanedial,Malonylaldehyde,Malonyldialdehyde,Sodium Malondialdehyde,Malondialdehyde, Sodium
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D003300 Copper A heavy metal trace element with the atomic symbol Cu, atomic number 29, and atomic weight 63.55. Copper-63,Copper 63
D004281 Docosahexaenoic Acids C22-unsaturated fatty acids found predominantly in FISH OILS. Docosahexaenoate,Docosahexaenoic Acid,Docosahexenoic Acids,Docosahexaenoic Acid (All-Z Isomer),Docosahexaenoic Acid Dimer (All-Z Isomer),Docosahexaenoic Acid, 3,6,9,12,15,18-Isomer,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer),Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Cerium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Cesium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(All-Z-Isomer), Potassium Salt,Docosahexaenoic Acid, 4,7,10,13,16,19-(Z,Z,Z,Z,Z,E-Isomer),Docosahexaenoic Acid, 4,7,10,13,16,19-Isomer,Docosahexaenoic Acid, 4,7,10,13,16,19-Isomer, Sodium Salt,Docosahexaenoic Acid, Sodium Salt,Acid, Docosahexaenoic,Acids, Docosahexaenoic,Acids, Docosahexenoic
D005227 Fatty Acids Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) Aliphatic Acid,Esterified Fatty Acid,Fatty Acid,Fatty Acids, Esterified,Fatty Acids, Saturated,Saturated Fatty Acid,Aliphatic Acids,Acid, Aliphatic,Acid, Esterified Fatty,Acid, Saturated Fatty,Esterified Fatty Acids,Fatty Acid, Esterified,Fatty Acid, Saturated,Saturated Fatty Acids
D005231 Fatty Acids, Unsaturated FATTY ACIDS in which the carbon chain contains one or more double or triple carbon-carbon bonds. Fatty Acids, Polyunsaturated,Polyunsaturated Fatty Acid,Unsaturated Fatty Acid,Polyunsaturated Fatty Acids,Acid, Polyunsaturated Fatty,Acid, Unsaturated Fatty,Acids, Polyunsaturated Fatty,Acids, Unsaturated Fatty,Fatty Acid, Polyunsaturated,Fatty Acid, Unsaturated,Unsaturated Fatty Acids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
January 1999, Life sciences,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
September 2000, Atherosclerosis,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
January 1994, Pharmacological research,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
May 1996, The American journal of clinical nutrition,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
April 1999, Atherosclerosis,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
January 1994, Life sciences,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
February 1993, Biochemical medicine and metabolic biology,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
September 1997, Annals of the New York Academy of Sciences,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
January 2013, Mediators of inflammation,
Catherine Calzada, and Romain Colas, and Nicolas Guillot, and Michel Guichardant, and Martine Laville, and Evelyne Véricel, and Michel Lagarde
April 1994, Lipids,
Copied contents to your clipboard!